|
1
|
Masuda T, Endo M, Yamamoto Y, Odagiri H,
Kadomatsu T, Nakamura T, Tanoue H, Ito H, Yugami M, Miyata K, et
al: ANGPTL2 increases bone metastasis of breast cancer cells
through enhancing CXCR4 signaling. Sci Rep. 5:91702015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siu MK, Tsai YC, Chang YS, Yin JJ, Suau F,
Chen WY and Liu YN: Transforming growth factor-β promotes prostate
bone metastasis through induction of microRNA-96 and activation of
the mTOR pathway. Oncogene. 34:4767–4776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang X, Li L, Huang Q, Xu W, Cai X, Zhang
J, Yan W, Song D, Liu T, Zhou W, et al: Wnt signaling through
Snail1 and Zeb1 regulates bone metastasis in lung cancer. Am J
Cancer Res. 5:748–755. 2015.PubMed/NCBI
|
|
4
|
Croucher PI, McDonald MM and Martin TJ:
Bone metastasis: the importance of the neighbourhood. Nat Rev
Cancer. 16:373–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Colden M, Dar AA, Saini S, Dahiya PV,
Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R and Majid S:
MicroRNA-466 inhibits tumor growth and bone metastasis in prostate
cancer by direct regulation of osteogenic transcription factor
RUNX2. Cell Death Dis. 8:e25722017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Westhoff PG, de Graeff A, Monninkhof EM,
Berveling MJ, van Vulpen M, Leer JWH, Marijnen CAM, Reyners AKL and
van der Linden YM; Dutch Bone Metastasis Study Group, : Screening
for psychological distress before radiotherapy for painful bone
metastases may be useful to identify patients with high levels of
distress. Acta Oncol. 56:1720–1727. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
von Moos R, Body JJ, Egerdie B, Stopeck A,
Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo
FS, et al: Pain and analgesic use associated with skeletal-related
events in patients with advanced cancer and bone metastases.
Support Care Cancer. 24:1327–1337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Porta-Sales J, Garzón-Rodríguez C,
Llorens-Torromé S, Brunelli C, Pigni A and Caraceni A: Evidence on
the analgesic role of bisphosphonates and denosumab in the
treatment of pain due to bone metastases: a systematic review
within the European Association for Palliative Care guidelines
project. Palliat Med. 31:5–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Inoue M, Otsuka K and Shibata H:
Circulating tumor cell count as a biomarker of a specific gastric
cancer subgroup characterized by bone metastasis and/or
disseminated intravascular coagulation - an early indicator of
chemotherapeutic response. Oncol Lett. 11:1294–1298. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alavi M, Omidvari S, Mehdizadeh A,
Jalilian AR and Bahrami-Samani A: Metastatic bone pain palliation
using (177)Lu-ethylenediaminetetramethylene phosphonic acid. World
J Nucl Med. 14:109–115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fischer M and Biersack HJ: Radionuclide
therapy of malignant bone lesions. Eur J Nucl Med Mol Imaging.
44:728–729. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lebret T, Casas A, Cavo M, Woll PJ,
Deleplace C, Kennedy C, Schoen P and Jackisch C: The use of
bisphosphonates in the management of bone involvement from solid
tumours and haematological malignancies - a European survey. Eur J
Cancer Care (Engl). 26:262017. View Article : Google Scholar
|
|
13
|
Singh T, Kaur V, Kumar M, Kaur P, Murthy
RS and Rawal RK: The critical role of bisphosphonates to target
bone cancer metastasis: an overview. J Drug Target. 23:1–15. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shapiro CL, Moriarty JP, Dusetzina S,
Himelstein AL, Foster JC, Grubbs SS, Novotny PJ and Borah BJ:
Cost-effectiveness analysis of monthly zoledronic acid, zoledronic
acid every 3 months, and monthly denosumab in women with breast
cancer and skeletal metastases: CALGB 70604 (Alliance). J Clin
Oncol. 35:3949–3955. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Glover D, Lipton A, Keller A, Miller AA,
Browning S, Fram RJ, George S, Zelenakas K, Macerata RS and Seaman
JJ: Intravenous pamidronate disodium treatment of bone metastases
in patients with breast cancer. A dose-seeking study. Cancer.
74:2949–2955. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Even-Sapir E: Imaging of malignant bone
involvement by morphologic, scintigraphic, and hybrid modalities. J
Nucl Med. 46:1356–1367. 2005.PubMed/NCBI
|
|
17
|
Hjermstad MJ, Fayers PM, Haugen DF,
Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N and Kaasa S;
European Palliative Care Research Collaborative (EPCRC), : Studies
comparing numerical rating scales, verbal rating scales, and visual
analogue scales for assessment of pain intensity in adults: a
systematic literature review. J Pain Symptom Manage. 41:1073–1093.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stopeck AT, Lipton A, Body JJ, Steger GG,
Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA,
Viniegra M, et al: Denosumab compared with zoledronic acid for the
treatment of bone metastases in patients with advanced breast
cancer: a randomized, double-blind study. J Clin Oncol.
28:5132–5139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Costa L and Major PP: Effect of
bisphosphonates on pain and quality of life in patients with bone
metastases. Nat Clin Pract Oncol. 6:163–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Body JJ, Casimiro S and Costa L: Targeting
bone metastases in prostate cancer: Improving clinical outcome. Nat
Rev Urol. 12:340–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu Y, Sun J, Yang X, Yu Y, Mai H and Li Z:
Pamidronate disodium leads to bone necrosis via suppression of
Wnt/β-catenin signaling in human bone marrow mesenchymal stem cells
in vitro. J Oral Maxillofac Surg. 75:2135–2143. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li P and Hu Y: ‘Turn-Off’ fluorescent
sensor for pamidronate disodium and zoledronic acid based on newly
synthesized carbon dots from black tea. J Anal Methods Chem.
2018:36312492018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goblirsch MJ, Zwolak PP and Clohisy DR:
Biology of bone cancer pain. Clin Cancer Res. 12:6231s–6235s. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lipton A, Small E, Saad F, Gleason D,
Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D and Seaman J:
The new bisphosphonate, Zometa (zoledronic acid), decreases
skeletal complications in both osteolytic and osteoblastic lesions:
a comparison to pamidronate. Cancer Invest. 20 (Suppl 2):45–54.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj
S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A and Braun
A: The role of denosumab in the prevention of hypercalcaemia of
malignancy in cancer patients with metastatic bone disease. Eur J
Cancer. 51:1467–1475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang S, Liu F, Zhu J, Chen P, Liu H, Liu Q
and Han J: DNA repair genes ERCC1 and BRCA1 expression in non-small
cell lung cancer chemotherapy drug resistance. Med Sci Monit.
22:1999–2005. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wong R and Wiffen PJ: Bisphosphonates for
the relief of pain secondary to bone metastases. Cochrane Database
Syst Rev. 2:CD0020682002.
|
